sulforadex

Sulforadex is a proprietary oral formulation consisting of synthetic sulforaphane stabilized with alpha-cyclodextrin (alfadex), developed to enhance the bioavailability and stability of sulforaphane for clinical use. Sulforaphane is a naturally occurring compound found in cruciferous vegetables like broccoli and is known as a potent activator of the Nrf2 antioxidant pathway. The alpha-cyclodextrin ring in Sulforadex protects the lipophilic sulforaphane molecule until it reaches the gastrointestinal tract, where it is cleaved to release active sulforaphane[1][4][6]. Mechanistically, Sulforadex acts through multiple pathways including activation of Nrf2 (by inhibiting KEAP1), inhibition of STAT3/pSTAT3 signaling relevant to cancer metastasis and resistance mechanisms, inhibition of SHP2 phosphatase activity involved in tumor progression and drug resistance, histone deacetylase (HDAC) inhibition affecting epigenetic regulation in cancer cells[5], androgen receptor antagonism[4], modulation of Hedgehog protein signaling[4], and Wnt pathway modulation[4]. It has been investigated for oncology indications such as breast cancer (including ER+ anti-estrogen therapy-resistant cases), glioblastoma, haematological malignancies; neurodevelopmental disorders; subarachnoid hemorrhage; SARS-CoV-2 acute respiratory disease; pervasive child development disorders; rhabdomyosarcoma; and other conditions characterized by oxidative stress or inflammation. Clinical trials have reached up to Phase II/III for some indications. The technology was originally developed by Evgen Pharma using their patented Sulforadex platform.

Brand names

Sulforadex

Other names

SFX-01SFX01SFX 01sulforafan alfadexsulforaphane-alpha-cyclodextrinstabilised sulforaphanesulphoraphane-alfadexbroccoli-sprout-extract